Although guidelines suggest prioritizing injectable GLP-1 RAs with documented cardiovascular benefits (liraglutide, injectable semaglutide, and dulaglutide), both the ADA and KDIGO do not currently recommend GLP-1 RAs specifically for kidney protection in patients with T2D and CKD [8,18]. This evidence concerns the gene GCG and chronic kidney disease.